Willow Biosciences (TSX: WLLW) appears to be backing up its proprietary IP with clinical trials. The company this morning announced positive results from its studies on its cannabigerol product, which demonstrated the safety of the product among other items.
The studies were conducted with Signum Biosciences, the firms development partner. Results from the study indicate that Willlow’s biosynthesized CBG product demonstrate anti-inflammatory, anti-aging and antimicrobial properties, while also being safe when applied to skin and eye areas. Furthermore, the product has been show to be more potent as both an anti-inflammatory and antioxidant when compared to cannabidiol that is plant derived.
Additionally, the compound reportedly demonstrates a robust safety profile, with no signs of skin irritation, eye irritation, or phototoxicity, enabling the compound to be utilized in skin care products. Following in vitro skin models, a clinical trial involving over 100 volunteers demonstrated that the product is safe for use on sensitive skin.
“Willow’s CBG is now clinically tested to be safe for sensitive skin and demonstrated in the laboratory to act as a potent antioxidant, anti-inflammatory and anti-microbial. Most interestingly, Willow CBG was shown to be as potent or more potent than CBD, in some cases up to twice as potent, in the performed assays. We believe the clinical work on human skin and in vitro models with CBG are the first of their kind to be reported and we are very excited to share the results with our stakeholders and industry.”
Dr Chris Savile, COO of Willow Biosciences
Full data collected from the studies is set to be released on May 3rd, 2021, with the company set to report the findings at the Society for Investigative Dermatology meeting that is to take place that same week.
Willow Biosciences last traded at $1.31 on the TSX.
FULL DISCLOSURE: Willow Biosciences Inc is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Willow Biosciences Inc on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
